Isochromanone-based urotensin-II receptor agonists

被引:28
|
作者
Lehmann, F
Currier, EA
Olsson, R
Hacksell, U
Luthman, K [1 ]
机构
[1] Univ Gothenburg, Dept Chem, SE-41296 Gothenburg, Sweden
[2] ACADIA Pharmaceut Inc, San Diego, CA 92121 USA
[3] ACADIA Pharmaceut AS, DK-2600 Glostrup, Denmark
关键词
D O I
10.1016/j.bmc.2005.01.056
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of analogues of the selective non-peptide urotensin II (UII) receptor agonist 3-(4-chlorophenyl)-3-(2-dimethylaminoethyl)-isochroman- 1-one (AC-7954, 1) was synthesized and evaluated for UII agonist activity using a functional cell-based assay. The introduction of a methyl group in the 4-position resulted in a complete loss of activity, whereas substituents in the aromatic rings were beneficial. Sterically demanding amino groups were also detrimental to the activity. Several potent agonists were identified, six compounds being equally or more potent than 1. The most potent compound in the series was the 6,7-dimethyl analogue of 1 (16, pEC(50) 6.87). The racemate of 16 was resolved into the pure enantiomers using preparative straight phase HPLC. It was shown that the potency resides in the (+)-enantiomer (pEC(50) 7.11). The synthesized compounds seem to be selective for the UII receptor as no activities were observed at the closely related SSTR3 and 5 receptors. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3057 / 3068
页数:12
相关论文
共 50 条
  • [21] Identification of new agonists of urotensin-II from a cyclic peptide library
    Odagami, Takenao
    Tsuda, Yuko
    Kogami, Yuji
    Kouji, Hiroyuki
    Okada, Yoshio
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (18) : 6742 - 6747
  • [22] Non-peptidic urotensin-II receptor modulators
    Jin, J
    Douglas, SA
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (04) : 467 - 479
  • [23] Ligand-Supported Purification of the Urotensin-II Receptor
    Du, Ann T.
    Onan, Doene
    Dinh, Diem T.
    Lew, Michael J.
    Ziogas, James
    Aguilar, Marie-Isabel
    Pattenden, Leonard K.
    Thomas, Walter G.
    MOLECULAR PHARMACOLOGY, 2010, 78 (04) : 639 - 647
  • [24] Discovery of new potent antagonist at urotensin-II receptor
    Sala, M.
    Auriemma, L.
    Campiglia, P.
    Monterrey-Gomez, I.
    Santicioli, P.
    Maggi, C. A.
    Rovero, P.
    Carotenuto, A.
    Novellino, E.
    Grieco, P.
    BIOPOLYMERS, 2007, 88 (04) : 604 - 604
  • [25] Urotensin-II gene polymorphism and serum urotensin-II levels in children with Bartter syndrome
    Balat, Ayse
    Koc, Gulsah
    Soyocak, Ahu
    Kilic, Beltinge Demircioglu
    Kara, Mehtap
    Buyukcelik, Mithat
    Noyan, Z. Aytul
    Bilge, Ilmay
    Ates, Funda Seher Ozalp
    PEDIATRIC NEPHROLOGY, 2024, 39 (01) : S346 - S346
  • [26] Behavioral actions of urotensin-II
    do Rego, Jean-Claude
    Leprince, Jerome
    Scalbert, Elizabeth
    Vaudry, Hubert
    Costentin, Jean
    PEPTIDES, 2008, 29 (05) : 838 - 844
  • [27] Is urotensin-II the new endothelin?
    Maguire, JJ
    Davenport, AP
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (05) : 579 - 588
  • [28] Urotensin-II and cardiovascular remodeling
    Papadopoulos, Panayiota
    Bousette, Nicolas
    Giaid, Adel
    PEPTIDES, 2008, 29 (05) : 764 - 769
  • [29] Urotensin-II as an angiogenic factor
    Guidolin, Diego
    Albertin, Giovanna
    Ribatti, Domenico
    PEPTIDES, 2010, 31 (06) : 1219 - 1224
  • [30] Urotensin-II and cardiovascular diseases
    Bousette, Nicolas
    Giaid, Adel
    CURRENT HYPERTENSION REPORTS, 2006, 8 (06) : 479 - 483